Rahul Lakhotia

Also affiliated with National Cancer Institute, Center for Cancer Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma”.

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2401532

N/A

1.5DataRank · unranked

68 citations

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Da Wei Huang, George W. Wright +31 more

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2021006397

N/A

1.3DataRank · unranked

44 citations

Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Nakhle S. Saba, Liza Lindenberg +11 more

Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL

Blood Advances(2021)10.1182/bloodadvances.2020003679

N/A

0.828DataRank · unranked

22 citations

Christopher Melani, Stefania Pittaluga, Rahul Lakhotia, Andrea N. Lucas, Allison P. Jacob +5 more

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology(2025)10.1111/bjh.20219

N/A

0.241DataRank · unranked

4 citations

Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan Muppidi +7 more

Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma—Where we are and where we’re headed

Seminars in Hematology(2025)10.1053/j.seminhematol.2026.02.003

N/A

0.241DataRank · unranked

4 citations

Mark Roschewski, Rahul Lakhotia

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Blood Neoplasia(2024)10.1016/j.bneo.2024.100054

N/A

0.165DataRank · unranked

2 citations

Sigrid Dubois, Miloš D. Miljković, Samuel Y. Ng, Bonita R. Bryant, Rahul Lakhotia +8 more

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)

Hematological Oncology(2023)10.1002/hon.3164_437

N/A

0.104DataRank · unranked

1 citations

Rahul Lakhotia, Stefania Pittaluga, J. D. Phelan, Y. Yang, Theresa Davies‐Hill +17 more

Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma

British Journal of Haematology(2025)10.1111/bjh.70234

N/A

0DataRank · unranked

1 citations

Rahul Lakhotia, Stefania Pittaluga, Svetlana Pack, Anna Marie Juanitez, Ahmed Hamdy +8 more

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Advances(2023)10.1182/bloodadvances.2023010223

N/A

0DataRank · unranked

0 citations

Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani +10 more

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Maryland Shared Open Access Repository (USMAI Consortium)(2024)10.13016/m2trio-fqf2

N/A

0DataRank · unranked

0 citations

Sigrid Dubois, Miloš Miljkovi?, Samuel Y. Ng, Bonita R Bryant, Rahul Lakhotia +8 more

Clinical applications of circulating tumor DNA in indolent B-cell lymphomas

Seminars in Hematology(2023)10.1053/j.seminhematol.2023.06.003

N/A

0DataRank · unranked

4 citations

Mark Roschewski, Rahul Lakhotia